Vanda Pharmaceuticals (VNDA) announced the FDA has granted Orphan Drug Designation for VGT-1849B, a selective peptide nucleic acid-based JAK2 inhibitor for the treatment of polycythemia vera. PV is a chronic myeloproliferative disorder characterized by aberrant hematopoiesis of myeloid lineage with exuberant red cell production and increased release of pro-inflammatory cytokines. The prevalence of PV in the United States is estimated to affect 44 to 57 per 100,000 people.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VNDA:
- Vanda Pharmaceuticals treatment of polycythemia vera granted orphan designation
- Vanda seeks FDA Commissioner review of Hetlioz generic ruling
- Vanda Pharmaceuticals’ Legal Victory and Potential HETLIOZ Approval Boosts Buy Rating
- Vanda Pharma granted favourable Court ruling over FDA’s Hetlioz approvability
- Strong Buy Rating for Vanda Pharmaceuticals Driven by Growth in Key Product Lines and Promising FDA Decision